Loading organizations...
§ Private Profile · Hafnarfjörður, Gullbringusysla, Iceland
Biotechnology company developing lipid nanoparticle (LNP) delivery systems for RNA therapeutics, focused on inflammatory and autoimmune diseases.
Axelyf is a biotechnology company based in Brookline, Massachusetts, with an R&D subsidiary in Reykjavik, Iceland, that develops next-generation lipid nanoparticle delivery systems for RNA therapeutics. The organization focuses on creating safer and more potent targeted treatments for inflammatory and autoimmune diseases by utilizing its proprietary AXL lipid library and an artificial intelligence design platform known as ANNA. In addition to advancing internal preclinical programs like its lead autoimmune candidate AXL-003, the enterprise actively collaborates with external pharmaceutical developers across the messenger RNA and gene-editing sectors. To support these ongoing research initiatives, the delivery-platform startup has raised $2.6 million in seed financing backed by lead investor Brunnur Ventures, alongside participation from Omega ehf and Silfurberg ehf. Axelyf was founded in 2022 by former Moderna executive Dr. Örn Almarsson, John Lucas, and Brynja Einarsdottir.
Axelyf has raised $2.6M across 1 funding round.
Axelyf has raised $2.6M in total across 1 funding round.
Axelyf has raised $2.6M across 1 funding round. Most recently, it raised $2.6M Seed in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 29, 2025 | $2.6M Seed | Arni Blöndal | Omega Venture Partners, Silfurberg | Announced |
Axelyf has raised $2.6M in total across 1 funding round.
Axelyf's investors include Arni Blöndal, Omega Venture Partners, Silfurberg.